Clinical Trial Update: Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Daratumumab with Velcade, Lenalidomide, and Dexamethasone versus Velcade, Lenalidomide, and Dexamethasone in previously untreated multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Stichting European Myeloma Network | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-24